Understanding Leukemias, Lymphomas and MyelomasRoutledge, 2017 M11 1 - 180 páginas An international team of contributors come together to present all clinically relevant aspects of leukemias, lymphomas, and myelomas. Using clear terminology, the book discusses salient features, diagnostic procedures, prognosis, and treatments for these cancers.Following on the successful steps of the first edition, this Second Edition covers:various types of leukemias, lymphomas, and myelomas utilizing stem cell transplantation side-effects of various treatments future prospects for leukemia, lymphoma, and myeloma targeted therapies and history of the cancers information and support sources for patients |
Contenido
Myths and Facts About Blood and Stem Cells | |
What Happens in Leukemias Lymphomas and Myelomas? | |
Different Types of Leukemias Lymphomas and Myelomas | xxi |
Diagnosis of Leukemia Lymphoma and Myeloma | 5-5 |
Specific Current Therapy for Myelomas | 5-93 |
Current Role of Stem Cell Transplantation for Leukemias Lymphomas and Myelomas | 5-108 |
Principal SideEffects of the Treatment of Leukemias Lymphomas and Myelomas | 11-18 |
Glossary | 11-31 |
Sources of Information and Support for Patients | 11-50 |
Otras ediciones - Ver todas
Understanding Leukemias, Lymphomas and Myelomas Tariq I. Mughal,Tariq Mughal,John Goldman,John M. Goldman,Sabena T. Mughal,Sabena Mughal Vista previa limitada - 2013 |
Understanding Leukemias, Lymphomas and Myelomas, Second Edition Tariq I. Mughal Sin vista previa disponible - 2010 |
Términos y frases comunes
abnormalities acute leukemia acute lymphoblastic leukemia acute myeloid leukemia adults allogeneic allogeneic SCT anemia antibody antigen associated autologous SCT B-cell lymphoma blood cancers bone marrow bortezomib Burkitt’s lymphoma cancer cancer cells cellular chemotherapy chromosome chronic lymphocytic leukemia chronic myeloid leukemia clinical trials combination complete remission cytarabine cytogenetic cytotoxic develop dexamethasone diagnosis disease donor dose drug effective Figure fludarabine follicular lymphoma G-CSF gene genetic GvHD hematological cancers hematopoietic high-dose Hodgkin lymphoma imatinib immune improve increased number induction infection inhibitors involved kinase lenalidomide lymph node lymphoid molecular monoclonal mutations myelodysplastic syndrome neutropenia normal overall survival particular patients with CML patients with myeloma peripheral blood phase photomicrograph of acute plasma cells platelet potential prognostic protein radiotherapy rare regimens relapse response risk rituximab role side-effects Source specialists specific stem cell transplant studies subtype T-cell thalidomide therapy tissue treated treatment tumor vincristine virus white blood cells